Compare AbbVie Inc (ABBV) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs State Street PDR S&P Retail ETF — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while State Street PDR S&P Retail ETF trades at $85.87. The key difference: AbbVie Inc pays a 2.72% dividend while State Street PDR S&P Retail ETF pays none, and AbbVie Inc is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | XRT | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $90.88 |
52-Week Low | $184.85 | $77.28 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
XRT trades at $87.62, down 0.5% on the day, with technical indicators showing a bullish bias from moving averages while oscillators remain neutral. The ETF faces mixed sentiment with recent downgrades citing macroeconomic headwinds despite strong retail sales data. Current price sits near key support at $87 with resistance at $88.
Outlook remains cautious as attractive valuation metrics conflict with consumer sentiment concerns. Investment opportunity exists in retail sector exposure but risks include negative real wage growth and high energy prices pressuring consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
